Amanote Research
Register
Sign In
Impact of Clinicopathological Characteristics on the Efficacy of Neoadjuvant Therapy in Patients With Human Epidermal Growth Factor Receptor-2-Positive Breast Cancer
International Journal of Cancer
- United States
doi 10.1002/ijc.31097
Full Text
Open PDF
Abstract
Available in
full text
Categories
Cancer Research
Oncology
Date
October 25, 2017
Authors
Bin Zhao
Hong Zhao
Publisher
Wiley
Related search
Expression of Growth Factor Receptor Family Before and After Targeted Therapy in Human Epidermal Growth Factor Receptor-2 Positive Breast Cancer Tissues
Korean Journal of Clinical Oncology
Cost-Effectiveness of Pertuzumab in Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer
Journal of Clinical Oncology
Cancer Research
Medicine
Oncology
Efficacy and Safety of Palbociclib Plus Endocrine Therapy in North American Women With Hormone Receptor‐positive/Human Epidermal Growth Factor Receptor 2‐negative Metastatic Breast Cancer
Breast Journal
Internal Medicine
Surgery
Oncology
The Role of Epidermal Growth Factor Receptor (EGFR) in the Efficacy of Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer Patients
Bulletin of Siberian Medicine
Molecular Medicine
Human Epidermal Growth Factor Receptor Expression in Colorectal Cancer and Its Relationship With Clinicopathological Characteristics
Middle East Journal of Digestive Diseases
Hepatology
Gastroenterology
Safety and Efficacy of Trastuzumab Emtansine in Advanced Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer: A Meta-Analysis
Scientific Reports
Multidisciplinary
Pertuzumab in Human Epidermal Growth-Factor Receptor 2-Positive Breast Cancer: Clinical and Economic Considerations
International Journal of Women's Health
Gynecology
Oncology
Midwifery
Maternity
Obstetrics
Human Epidermal Growth Factor Receptor 2-Targeted Therapies in Breast Cancer
Expert Opinion on Biological Therapy
Drug Discovery
Clinical Biochemistry
Pharmacology
Substituting Adjuvant Trastuzumab Emtansine for Herceptin Improves Survival in Patients With Human Epidermal Growth Factor Receptor 2–positive Breast Cancer
Cancer
Cancer Research
Oncology
